- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
CAR T Cells Targeting Mesothelin Show Strong Early Signal in Advanced Solid Cancers
April 1st 2019, 1:13am
CAR T cells targeting mesothelin-expressing tumors demonstrated safety and efficacy in a preliminary clinical evaluation in patients with malignant pleural disease.
CAR T-Cell Therapy and Lymphodepletion Shows Early Efficacy, Tolerability in Advanced Sarcoma
April 1st 2019, 12:17am
The administration of HER2-directed CAR T-cell therapy and lymphodepletion chemotherapy demonstrated antitumor activity and was found to be safe in pediatric and adult patients with advanced HER2-positive sarcoma.
Testing, Treatment Options Added to NCCN CRC Guidelines
March 25th 2019, 1:24am
A theme of the 2019 NCCN Annual Conference was the expansion of biomarker testing to guide treatment, and a review of brand-new changes for guidelines in colorectal cancer was no different.
Dr. Naidoo Discusses Biomarker Testing for Checkpoint Inhibitors
March 24th 2019, 10:24pm
Jarushka Naidoo, MD, BCh, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.
Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCC
March 24th 2019, 10:18pm
Anthony J. Olszanski, MD, RPh, discusses the treatment selection process for use of cemiplimab in patients with cutaneous squamous cell carcinoma.
PARP Inhibition Strategies Refined in Ovarian Cancer Guidelines
March 24th 2019, 10:09pm
An updated guideline (version 1.2019) from the NCCN for the management of ovarian cancer recommends specific PARP inhibitors for the treatment of recurrent disease, describes patient selection criteria for each agent, and establishes criteria for PARP inhibitor maintenance therapy.
Bladder Cancer Guidelines Showcase Advent of Immunotherapy
March 24th 2019, 9:59pm
Thomas W. Flaig, MD, discusses the latest updates to the NCCN guidelines for the treatment of patients with muscle-invasive bladder cancer and highlights the latest approvals of checkpoint inhibitors in this patient population.
PD-L1 Status Central to NCCN Update for Frontline NSCLC Immunotherapy
March 23rd 2019, 10:39pm
PD-L1 testing, while an imperfect biomarker, is the key determinant of frontline immunotherapy selection in the NCCN guidelines for non–small cell lung cancer.
TKI Discontinuation Criteria Established in Updated NCCN CML Guideline
March 23rd 2019, 8:21pm
With careful monitoring, discontinuation of TKI therapy is considered safe in adult patients with chronic myeloid leukemia in the chronic phase, who achieve and maintain a major molecular response.
NCCN Guidelines Update Increases Role of Genetic Testing in Prostate Cancer
March 23rd 2019, 6:43pm
Emmanuel S. Antonarakis, MD, discusses the prevalence of mismatch repair and homologous recombination deficiency genes and how they may play a role in determining a patient’s treatment plan in addition to promising agents that have been introduced to the field in clinical trials.
Dr. Nabors on Evolving Treatment Options for Brain Metastases
March 23rd 2019, 12:42am
Louis B. Nabors, MD, of University of Alabama, Birmingham Comprehensive Cancer Center, discusses the evolving treatment landscape for patients with brain metastases.
Expert Addresses Therapeutic Updates for Breast Cancer Subtypes
March 22nd 2019, 10:37pm
William J. Gradishar, MD, discusses the latest updates in HER2-negative advanced breast cancer and the role of molecular assays in this space.
Germline Testing Emphasized in NCCN Guidelines on Pancreatic Cancer
March 22nd 2019, 10:24pm
In recent years, pancreatic has passed breast cancer as the third leading cause of cancer death in the United States, and by 2030 it could be the leading cause.
Frontline Combos Poised to Change NCCN Guidelines in Advanced RCC
March 22nd 2019, 8:56pm
The 2019 National Comprehensive Cancer Network guideline on the management of advanced clear cell renal cell carcinoma undergoes a major shift in risk category used to define preferred and alternative first-line treatments.
Dr. Ward on Multigene Testing in Breast Cancer
March 22nd 2019, 7:54pm
John H. Ward, MD, discusses his preferences in multilane testing for patients with hormone receptor–positive, node-negative breast cancer.
Dr. Lyman on the Process for Approving Biosimilars
March 22nd 2019, 7:34pm
Gary H. Lyman, MD, MPH, medical oncologist, Fred Hutchinson Cancer Research Center, discusses the differences in approving a biosimilar and the original biologic product during the 2019 NCCN Annual Conference.
Dr. Gubens Discusses the Role of PD-L1 in Patients With NSCLC
March 21st 2019, 11:34pm
Matthew A. Gubens, MD, MS, discusses an update to the NCCN Guidelines regarding patients with PD-L1 non–small cell lung cancer.
Dostarlimab Yields Durable Response in MSI-H, MSS Endometrial Cancer
March 20th 2019, 1:14am
Patients with recurrent or advanced endometrial cancer demonstrated an overall response rate of almost 30% with dostarlimab treatment.
Olaparib Plus Neratinib Shows Early Potential in HER2+ Ovarian Cancer
March 19th 2019, 11:32pm
Combination use of olaparib and neratinib may represent a novel therapeutic option for chemotherapy-resistant patients with HER2-positive, homologous recombination–proficient ovarian cancer tumors.
Adding Dendritic Cell-Based Immunotherapy to Chemo Improves OS in Relapsed Ovarian Cancer
March 19th 2019, 9:55pm
The addition of the dendritic cell-based immunotherapy DCVAC/OvCA to standard carboplatin and gemcitabine led to a significant improvement in overall survival in patients with relapsed, platinum-sensitive, epithelial ovarian cancer.